Houston's Welch Foundation has awarded more than 80 grants to support chemical research and careers in Texas for 2025. Photo via Getty Images

Houston-based The Welch Foundation has doled out $27 million in its latest round of grants for chemical research, equipment and postdoctoral fellowships.

According to a June announcement, $25.5 million was allocated for the foundation's longstanding research grants, which provide $100,000 per year in funding for three years to full-time, regular tenure or tenure-track faculty members in Texas. The foundation made 85 grants to faculty at 16 Texas institutions for 2025, including:

  • Michael I. Jacobs, assistant professor in the chemistry and biochemistry department at Texas State University, who is investigating the structure and thermodynamics of intrinsically disordered proteins, which could "reveal clues about how life began," according to the foundation.
  • Kendra K. Frederick, assistant professor in the biophysics department at The University of Texas Southwestern Medical Center, who is studying a protein linked to Parkinson’s disease.
  • Jennifer S. Brodbelt, professor in chemistry at The University of Texas at Austin, who is testing a theory called full replica symmetry breaking (fullRSB) on glass-like materials, which has implications for complex systems in physics, chemistry and biology.

Additional funding will be allocated to the Welch Postdoctoral Fellows of the Life Sciences Research Foundation. The program provides three-year fellowships to recent PhD graduates to support clinical research careers in Texas. Two fellows from Rice University and Baylor University will receive $100,000 annually for three years.

The Welch Foundation also issued $975,000 through its equipment grant program to 13 institutions to help them develop "richer laboratory experience(s)." The universities matched funds of $352,346.

Since 1954, the Welch Foundation has contributed over $1.1 billion for Texas-nurtured advancements in chemistry through research grants, endowed chairs and other chemistry-related ventures. Last year, the foundation granted more than $40.5 million in academic research grants, equipment grants and fellowships.

“Through funding basic chemical research, we are actively investing in the future of humankind,” Adam Kuspa, president of The Welch Foundation, said the news release. “We are proud to support so many talented researchers across Texas and continue to be inspired by the important work they complete every day.”

In all, the Welch Foundation on June 4 announced more than $40.5 million in academic research grants, equipment grants, and fellowships. Photo via Getty Images

Texas organization grants over $40M to chemistry research in Houston and beyond

fresh funding

Two local professors are among the newly announced recipients of funding from the Houston-based Welch Foundation, which finances chemical research projects.

The two professors are:

  • Jacinta Conrad, the Frank M. Tiller Professor in the Chemical and Biomolecular Engineering Department at the University of Houston. Conrad will use her grant to investigate glass transition, a temperature change that affects polymers. She describes glass transition as one of the “most intriguing open problems in physical chemistry.”
  • James Shee, assistant professor in the Chemistry Department at Rice University. Shee will put his grant toward advancing theoretical chemistry.

Every year, the foundation provides annual grants totaling at least $100,000 to support chemistry research being carried out by full-time faculty members at colleges, universities, and other educational institutions in Texas.

In all, the Welch Foundation on June 4 announced more than $40.5 million in academic research grants, equipment grants, and fellowships.

Part of the announced funding will go toward the foundation’s new Postdoctoral Fellows Grant Program. The program provides three-year fellowships to recent PhD graduates to support clinical research careers in Texas. A total of $900,000 in postdoctoral fellowships were funded at Rice University, Texas A&M University, and the University of Texas at Austin.

Since 1954, the Welch Foundation has contributed over $1.1 billion for Texas-nurtured advancements in chemistry through research grants, endowed chairs, and other chemistry-related ventures.

“Ongoing basic chemical research is critically important for helping to solve current and future problems,” said Adam Kuspa, President of the Welch Foundation. “We strongly believe the foundation’s continued support of the research grant program, combined with … new programs, will yield even more exciting developments as we work to advance chemistry and improve our lives.”

The Welch Foundation, a Houston-based nonprofit, has doled out fresh funding to research organizations, with over a third being deployed to Houston-area institutions. Photo via Getty Images

Houston organization announces nearly $28M in Texas research grant funding

money moves

Five schools in the Houston area have landed $10.8 million in research grants from the Houston-based Welch Foundation.

The 36 grants were awarded to Rice University, Texas A&M University, the University of Houston, the Baylor College of Medicine, and the University of Texas Medical Branch in Galveston.

In all, the foundation announced nearly $28 million in Texas research grants for 2023. All of the money — in the form of 91 grants for 15 Texas colleges and universities — goes toward chemical research. This year’s total for grant funding matches last year’s total.

“The Welch Foundation continues to emphasize the creative pursuit of basic chemical research,” Adam Kuspa, the foundation’s president and a former dean at the Baylor College of Medicine, says in a news release. “Our funding allows investigators throughout the state to follow their curiosity and explore the foundations chemical processes.”

Since its establishment in 1954, the Welch Foundation has contributed about $1.1 billion to the advancement of chemistry in Texas.

One of this year’s local grant recipients is Haotian Wang, assistant professor in Rice’s chemical and biomolecular department. The professor’s grant-funded research will focus on the conversion of carbon dioxide into useful chemicals, such as ethanol.

Last year, Rice reported that Wang’s lab in the George R. Brown School of Engineering had replaced rare, expensive iridium with ruthenium, a more abundant precious metal, as the positive-electrode catalyst in a reactor that splits water into hydrogen and oxygen.

The lab’s addition of nickel to ruthenium dioxide resulted in production of hydrogen from water electrolysis for thousands of hours.

“There’s huge industry interest in clean hydrogen,” Wang says. “It’s an important energy carrier and also important for chemical fabrication, but its current production contributes a significant portion of carbon emissions in the chemical manufacturing sector globally.”

“We want to produce it in a more sustainable way,” he adds, “and water-splitting using clean electricity is widely recognized as the most promising option.”

Houston-based Welch Foundation has awarded almost $28 million in chemical research grants throughout Texas this year. Photo via Getty Images

Houston research organization doles out $28M in grants to innovators across Texas

funding for the future

Chemical researchers at seven institutions in the Houston area are receiving nearly $12.9 million grants from the Houston-based Welch Foundation.

In the Houston area, 43 grants are going to seven institutions:

  • Baylor College of Medicine
  • Rice University
  • Texas A&M University
  • Texas A&M University Health Science Center
  • University of Houston
  • University of Texas Health Science Center at Houston
  • University of Texas Medical Branch in Galveston

The Welch Foundation is awarding almost $28 million in chemical research grants throughout Texas this year. The money will be allocated over a three-year period.

“Today, chemical research is more important than ever for improving the human condition and for meeting the global challenges that threaten our collective future,” says Adam Kuspa, president of the Welch Foundation. “Basic research in chemistry and related fields provides the foundation for groundbreaking scientific discoveries that can help solve current problems and sustain progress.”

Two of the 2022 grant recipients cited by the foundation are:

  • Josephine Chu Ferreon, assistant professor of pharmacology and chemical Biology at the Baylor College of Medicine. She plans to use her Welch grant to conduct research on intrinsically disordered proteins (IDPs) and their potential applications in biotech and nanomedicine. IDPs, known as “dancing proteins,” do not form uniquely defined 3D structures. Because of the structural flexibility, IDPs can pair with ordered proteins to perform functions that structured proteins can’t do on their own.
  • David Powers, assistant professor of chemistry at Texas A&M. He leads a research group focused on the relationship between organic and inorganic chemistry. Members of the group are trying to develop new methods for the sustainable synthesis of functional molecules.

Since its establishment in 1954, the Welch Foundation has contributed more than $1.1 billion to the advancement of chemistry in Texas. Last year, the organization granted $23 million in funds.

The Welch Foundation has announced millions in Texas research funding. Photo via Getty Images

Houston-based research grant program doles out $23M to Texas scientists

funds for the future

One of the nation's largest private funders for health care research has announced $23 million in fresh funds — and about a third of that is going into the hands of Houstonians.

The Welch Foundation, based in Houston, announced its 2021 research grant funding last week. Over the next three years, the funds will be be distributed in $7,520,000 payouts annually across the state of Texas. Since its founding in 1954, the foundation has doled out almost $1.1 billion to the advancement of chemistry.

"Ongoing basic chemical research is critical and provides the building blocks to help solve current and future problems," says Adam Kuspa, president of The Welch Foundation, in a news release. "Funding from The Welch Foundation is a valuable resource to Texas institutions. It helps set our state's researchers apart from others and we look forward to seeing what invaluable scientific contributions come from this year's grant recipients."

The universities in the Houston area that received a cut of this chunk of funding include Rice University, Texas A&M University, University of Houston, and Baylor College of Medicine for a total of $8,400,000 across 35 grants.

One of the Houston-area researchers who received funding is Leila Romero, assistant professor and CPRIT Scholar in Cancer Research at Baylor University's Department of Chemistry and Biochemistry. Romero and her team is exploring modes of asymmetric catalysis and to study how these new processes work. According to the release, the funding will also support the training of young graduate students at the institution who are on track to become future innovators in chemical synthesis.

Other Texas institutions in other major cities also received funding:

  • The Dallas/Fort Worth area received funding for 42 grants, totaling $10,080,000. The University of Texas Southwestern Medical Center, The University of Texas at Dallas, University of North Texas, Baylor University, Southern Methodist University, and Texas Christian University were the recipient institutions.
  • In Austin, the University of Texas Received funding for 11 grants, totaling $2,640,000.
  • The University of Texas at San Antonio and Trinity University received the three grants — totaling $720,000 — that went to the San Antonio area.
  • In West Texas, The University of Texas at El Paso received funding for 1 grant, totaling $240,000.
  • Texas Tech University received funding for two grants, totaling $480,000

Last year, the Welch Foundation announced a $100 million gift to Rice University to establish The Welch Institute. The institute will foster the study of matter, the design and discovery of new materials, and nanotechnology, and it will be led by an independent board of directors and scientific advisory board.

Kuspa, who's led the foundation since September 2019, joined the Houston Innovators Podcast last December to discuss the new institute and the importance of supporting researchers in Texas.


This week's innovators to know roundup includes Heath Butler and Samantha Lewis of Mercury Fund and Adam Kuspa of the Welch Foundation. Photos courtesy

3 Houston innovators to know this week

who's who

Editor's note: In this week's Monday roundup of Houston innovators, I'm introducing you to three innovators across the city — each in their own ways financially support the region's top innovators.


Heath Butler and Samantha Lewis of Mercury Fund

Heath Butler has been promoted to managing director of Mercury Fund, and Samantha Lewis joins the firm as principal. Photos courtesy

Houston-based Mercury Fund, which focuses on early-stage startups located in central United States, announced the promotion of Heath Butler to managing director from network partner. Additionally, Samantha Lewis — formerly investment director at Houston-based Goose Capital — is joining the fund as principal.

"Over the past few years, we've continued to build our investment team with top talent from our ecosystem," says Blair Garrou, co-founder and managing director of Mercury, in a news release.

"The promotion of Heath and the addition of Samantha will further Mercury's early-stage venture leadership in Middle America, and is illustrative of Mercury's deep commitment to diversity as a core value driver," continues Garrou. Click here to read more.

Adam Kuspa of The Welch Foundation

Adam Kuspa of The Welch Foundation joins the Houston Innovators Podcast to discuss the COVID-19 vaccine, materials science, and more. Photo courtesy of The Welch Foundation

It's been an interesting year for Adam Kuspa and the Welch Foundation as — just like any other organization — the pandemic has caused various disruptions for Kuspa and his team. At the same time, COVID-19 has forced an unprecedented public-private response from the medical community, the government, and more.

"I'm very proud of the scientific enterprise in this country and around the world — they way it's been supported, developed, and maintained over the years — to allow for something like this be even contemplated," Kuspa says on this week's episode of the Houston Innovators Podcast.

Over the last 40 to 50 years, researchers in the fields immunology, vaccine research, protein biochemistry, and more, have seen increased support, Kuspa says, and that's what made a difference in the pandemic and allowed for a vaccine to emerge so quickly. Click here to read more and to listen to the episode.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Houston researchers develop dissolvable implant for targeted cancer drug delivery

cancer research

Researchers at Houston Methodist have developed a biodegradable implant that can be used to safely and consistently deliver drug treatments to tumors and then dissolve without the need for further surgery.

The implant is only the size of a grain of rice, but its potential is staggering. The biodegradable nanofibrous drug-eluting seed (b-NDES) works as a reservoir parked inside a soft tumor, where it can slowly release immune-stimulating drugs over time. This overcomes a consistent problem with drugs such as immune checkpoint inhibitors. Normal systemic administration sees comparatively little of the drug making its way to the tumor, with most of it circulating throughout the body. The b-NDES is like deploying a small guerrilla fighting force embedded in enemy territory, doing maximum damage to the entrenched tumor.

"To improve cancer treatment, we're trying to start a fire inside the tumor itself," Corrine Chua, associate professor in the Center for BioNanoengineering at Houston Methodist Research Institute, said in a news release. "By activating immune cells directly within the tumor microenvironment, those cells can then travel throughout the body and seek out cancer wherever it exists. The b-NDES platform was developed to help keep therapeutic drugs concentrated inside tumors while minimizing exposure to healthy tissues.”

Chua co-led the study with Alessandro Grattoni, chair and director of the Center for BioNanoengineering at Houston Methodist Research Institute.

The study included support from the Nancy Owens Breast Cancer Foundation and the National Institutes of Health/National Cancer Institute.

Chau and Grattoni used preclinical models of triple-negative breast cancer, an aggressive form of cancer that is estrogen receptor-negative, progesterone receptor-negative and HER2-negative. Because of the receptor negativity, some popular treatments like tamoxifen and trastuzumab are ineffective. Chemotherapy has been shown to be the best course of action.

The b-NDES implant is deployed alongside radiation drugs. It keeps the drugs focused on the tumor, reducing the amount of harmful side effects typically seen when drugs are circulated more widely in the body. In 60 percent of the models, tumors were eliminated and did not cause side effects beyond the tumor site. Once the drugs have been deployed, the implant breaks down naturally.

While promising, more research will have to be done to expand use to other tumor types.

"Although the study focused on triple-negative breast cancer models, the approach could have broader applications for solid tumors," Grattoni added in the release. "It could potentially be used in cancers where there is a tumor lesion accessible for placement, including pancreatic or lung cancers."

New Houston platform Same Day Reels launches for on-demand content creation

In The Moment

If an event doesn't happen on Instagram, did it even really happen? In today's social media-driven age of branding and audience engagement, the answer increasingly is no.

Houston entrepreneur Karen De Amat is looking to fill the online content creation needs of companies with her new venture, Same Day Reels, which launched in early August. It will serve as a platform to connect companies and brands with talent that can help turn an event into a viral moment as it is happening.

"Events move quickly, and social media moves even faster,” said De Amat. “Same Day Reels was built to help brands capture the moment while it still matters. We are creating a more efficient way for businesses and creators to work together. Brands need content faster, and creators need more opportunities to turn their talent into real work. Same Day Reels brings those needs together.”

The company is focused on adding livestreams and concurrent short video content to "activations, launches, fundraisers, grand openings, conferences, hospitality experiences, and private celebrations." Such content can significantly increase the visibility of a product or brand according to digital marketing brands like Wyzowl, whose data found 63 percent of people in 2026 prefer to learn about new products via short video.

Packages offered by Same Day Reels will include filming, editing, and publishing content within hours of the targeted event.

De Amat says that her content creation platform will be a way to preserve the excitement of events and launches by enshrining them with immediate social media-driven memories.

“Event content is no longer just something you post after the fact,” De Amat said. “It is part of how people experience, remember and share the moment.”

Previously, De Amat is also the founder and CEO of Social Behavior, an influencer marketing company she launched from her home in 2014. It quickly garnered an array of clients and thrust De Amat into the spotlight, including numerous appearances on Fox 26's The Isiah Factor. Influencer Marketing Hub named her one of the top CEOs of influencer marketing companies in Houston in 2025.

---

This article originally appeared on CultureMap.com.

Bristol Myers Squibb to build $2.3B Houston pharma manufacturing campus

coming soon

New Jersey-based pharmaceutical giant Bristol Myers Squibb Co. has officially named Houston as the home of its new state-of-the-art manufacturing site.

The 60,000-square-foot facility represents a $2.3 billion investment, according to a news release. It is expected to create 500 skilled jobs and will be located in Houston's Generation Park.

BMS first announced that it was considering Houston among 16 other cities for the facility in May. The new hub will manufacture small molecule, biologic and antibody-drug conjugates and is part of a $40 billion commitment to invest in the United States over five years. Construction is slated to begin next year, with the facility coming online in 2030.

"We're building the domestic manufacturing capabilities needed to deliver the next generation of medicines and support future scientific breakthroughs. Houston and the state of Texas offer the talent, infrastructure, and partnership needed to help bring that vision to life," Christopher Boerner, CEO and board chair of BMS, said in the release.

The new facility will feature a modular, multi-modal design, which will allow the company to reconfigure and add to its manufacturing capabilities over time. BMS says it expects the facility to "(grow) in scale and capability well beyond its opening configuration."

"Our decision to build this state-of-the-art manufacturing campus in Houston, Texas, reflects our confidence in the region’s ability to support a world-class, digitally advanced supply operation,” Karin Shanahan, EVP and chief supply chain and operations officer of BMS, added in the release. “This facility is designed to deliver the speed, quality, and reliability that patients depend on, combining flexible, modular manufacturing with advanced digital capabilities to ensure consistent supply across multiple modalities. It strengthens our ability to operate with resilience and positions us to reliably deliver medicines to patients today while adapting future demands.”

Texas Gov. Greg Abbott shared that the state has granted BMS a $4.89 million Texas Enterprise Fund (TEF) grant for the project. TEF grants, administered by the Texas Economic Development & Tourism Office, support business relocation or expansion projects that create "new, good-paying jobs in the community and attract significant new capital investment to the state." The development is also a qualified project under the Texas Jobs, Energy, Technology, and Innovation (JETI) program.

“Texas is a global hub for life sciences, where today’s innovations shape the future of healthcare,” Abbott said in a news release. “This $2.3 billion investment by Bristol Myers Squibb in the dynamic biotech ecosystem in Houston is a testament to the depth of our skilled workforce and the pipeline of talent coming through our nation-leading technical colleges and research universities. With lower operating costs and easy access to markets across the U.S. and the world, Texas drives affordability for consumers.”

"Bristol Myers Squibb’s announcement is a tremendous win for Texas and the Houston region, further reinforcing our position as a premier destination for life sciences and advanced manufacturing,” added Greater Houston Partnership President and CEO Steve Kean.

Last fall, Eli Lilly and Co. selected Generation Park, a 4,300-acre, master-planned commercial district near Lake Houston, for its $6.5 billion manufacturing plant. More than 300 locations in the U.S. competed for the factory. Read more here.